The pharmacist’s new role in the opioid epidemic: showing customers how to reverse overdoses

In the midst of the opioid epidemic, more pharmacists are receiving naloxone training to teach their customers how to use the overdose reversal treatment, according to STAT.

Advertisement

Pharmacists are getting certified to administer naloxone in response to the opioid epidemic.

Surgeon General Jerome Adams, MD, has urged that naloxone become universally available.

Pharmacists previously have helped combat the opioid epidemic by counseling patients who have beenprescribed high-dose opioids and taking part in drug-monitoring programs  to make sure they are not prescribed risky combinations of other drugs with pain medication. Showing patients how to use naloxone is a new frontier.

“We all have fire extinguishers,” Sarah Melton,MD, a professor of pharmacy at East Tennessee State University and the lead trainer at a recent conference that taught pharmacists how to assemble naloxone kits and administer it, told STAT.

Like that fire extinguisher, naloxone is a logical precaution pharmacists can use to help their customers become “lay rescuers,” Ms. Melton said.

More articles on pharmacy:

5 recent pharma layoffs
Novartis has spent $15B to reinvent itself
AstraZeneca starts search for new CEO under pressure from stakeholders

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.